HVB MINI FUTURE BULL - ASTRAZENECA | Delayed Deutsche Boerse AG 05:44:53 2024-05-29 EDT | ||
| 5.26 EUR | -0.38% |
|
| Current month | -1.12% | ||
| 1 month | -1.12% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-05-29 | 5.26 | -0.38% |
| 24-05-28 | 5.28 | -6.05% |
| 24-05-27 | 5.62 | -0.53% |
| 24-05-24 | 5.65 | -1.05% |
| 24-05-23 | 5.71 | +1.06% |
Delayed Quote Deutsche Boerse AG
Last update May 29, 2024 at 05:44 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HR6WGF |
| ISIN | DE000HR6WGF8 |
| Date issued | 2021-04-16 |
| Strike | 7,502 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.89 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.05 € |
|---|---|
| Lowest since issue | 0.8 € |
| Spread | 0.01 € |
| Spread % | 0.19% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.7
USD
Average target price
170.1
USD
Spread / Average Target
+10.69%
- Stock Market
- Certificates
- Certificat
